The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study.
Bleeding abnormality
Blood coagulation disorder
Factor VIII
Healthcare expenditures
Socioeconomic factors
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
12
12
2022
accepted:
02
04
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
Haemophilia A carries a substantial healthcare burden, affecting health-related quality of life (HRQoL). The Cost of Haemophilia in Men: a Socioeconomic Survey II (CHESS II), a retrospective real-world study, characterised the burden of haemophilia and its impact on HRQoL and work productivity. The current analysis explored the impact of bleeding events on HRQoL and work productivity in Europe. This analysis focused on data collected from males aged 18 to 64 years with haemophilia A without inhibitors who were receiving replacement factor products or a monoclonal antibody and were not participating in a clinical trial at the time of study recruitment. Descriptive statistics were analysed using scores from EuroQoL's EQ-5D-5L index and EQ-VAS analogue scale and the Work Productivity and Activity Index Specific Health Problem (WPAI:SHP) percentage scores stratified by the number of annual bleeding events (ABs) 0, 1, 2, 3-4, or ≥ 5. Of 918 males with haemophilia A in CHESS II, 318 met inclusion criteria and had data available for HRQoL measures; mean age (SD) was 33.8 (12.1) years and 96% were White. Mean (SD) ABs of 2.7 (2.9) occurred over the preceding 12 months: 20% had 3 or 4 ABs; 17% had ≥ 5 ABs. Mean EQ-5D-5L index scores for patients with 0, 1, 2, 3-4, or ≥ 5 ABs were 0.92, 0.76, 0.76, 0.71, and 0.56, respectively. Mean (SD) EQ-VAS scores were 86.9 (13.6), with 0 ABs versus 69.5 (19.1) for 3 or 4 ABs and 61.2 (17.2) for ≥ 5 ABs. Mean percentage of overall work productivity loss on the WPAI:SHP questionnaire ranged from 9.70 to 0 ABs to 47.65 for ≥ 5 ABs. In this European sample of adult men with haemophilia A, HRQoL and work productivity scores were lower among those reporting more AB events. Bleeding burden appears to affect HRQoL and productivity; however, this cross-sectional analysis limits the ability to draw firm conclusions on causality.
Sections du résumé
BACKGROUND
Haemophilia A carries a substantial healthcare burden, affecting health-related quality of life (HRQoL). The Cost of Haemophilia in Men: a Socioeconomic Survey II (CHESS II), a retrospective real-world study, characterised the burden of haemophilia and its impact on HRQoL and work productivity. The current analysis explored the impact of bleeding events on HRQoL and work productivity in Europe. This analysis focused on data collected from males aged 18 to 64 years with haemophilia A without inhibitors who were receiving replacement factor products or a monoclonal antibody and were not participating in a clinical trial at the time of study recruitment. Descriptive statistics were analysed using scores from EuroQoL's EQ-5D-5L index and EQ-VAS analogue scale and the Work Productivity and Activity Index Specific Health Problem (WPAI:SHP) percentage scores stratified by the number of annual bleeding events (ABs) 0, 1, 2, 3-4, or ≥ 5.
RESULTS
Of 918 males with haemophilia A in CHESS II, 318 met inclusion criteria and had data available for HRQoL measures; mean age (SD) was 33.8 (12.1) years and 96% were White. Mean (SD) ABs of 2.7 (2.9) occurred over the preceding 12 months: 20% had 3 or 4 ABs; 17% had ≥ 5 ABs. Mean EQ-5D-5L index scores for patients with 0, 1, 2, 3-4, or ≥ 5 ABs were 0.92, 0.76, 0.76, 0.71, and 0.56, respectively. Mean (SD) EQ-VAS scores were 86.9 (13.6), with 0 ABs versus 69.5 (19.1) for 3 or 4 ABs and 61.2 (17.2) for ≥ 5 ABs. Mean percentage of overall work productivity loss on the WPAI:SHP questionnaire ranged from 9.70 to 0 ABs to 47.65 for ≥ 5 ABs.
CONCLUSIONS
In this European sample of adult men with haemophilia A, HRQoL and work productivity scores were lower among those reporting more AB events. Bleeding burden appears to affect HRQoL and productivity; however, this cross-sectional analysis limits the ability to draw firm conclusions on causality.
Identifiants
pubmed: 37537683
doi: 10.1186/s13023-023-02690-w
pii: 10.1186/s13023-023-02690-w
pmc: PMC10398941
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
227Informations de copyright
© 2023. Institut National de la Santé et de la Recherche Médicale (INSERM).
Références
Value Health. 2017 Sep;20(8):1074-1082
pubmed: 28964439
Haemophilia. 2020 Aug;26 Suppl 6:1-158
pubmed: 32744769
Haemophilia. 2019 Sep;25(5):738-746
pubmed: 31282050
Haemophilia. 2021 Nov;27(6):938-946
pubmed: 34273215
Patient Prefer Adherence. 2015 Oct 29;9:1549-60
pubmed: 26604708
Swiss Med Wkly. 2020 Dec 18;150:w20422
pubmed: 33338252
J Cardiothorac Vasc Anesth. 2022 Jan;36(1):246-257
pubmed: 33082094
Haemophilia. 1999 May;5(3):216-9
pubmed: 10484669
Orphanet J Rare Dis. 2022 Apr 4;17(1):148
pubmed: 35379282
J Thromb Haemost. 2018 Nov;16(11):2184-2195
pubmed: 30137664
J Thromb Haemost. 2018 Sep;16(9):1722-1731
pubmed: 29908043
J Med Econ. 2015 Jun;18(6):457-65
pubmed: 25660324
N Engl J Med. 2017 Aug 31;377(9):809-818
pubmed: 28691557
J Blood Med. 2022 May 09;13:229-241
pubmed: 35585877
Rheumatology (Oxford). 2010 Apr;49(4):812-9
pubmed: 20100797
Lancet. 2021 Feb 13;397(10274):630-640
pubmed: 33460559
Am J Manag Care. 2016 Apr;22(5 Suppl):s126-33
pubmed: 27266809
Haemophilia. 2018 May;24(3):344-347
pubmed: 30070072
N Engl J Med. 2020 Sep 10;383(11):1018-1027
pubmed: 32905674
J Thromb Haemost. 2021 Jun;19(6):1436-1446
pubmed: 33587824
Ther Adv Hematol. 2018 Feb;9(2):49-61
pubmed: 29387330
Clin Ther. 2008 Feb;30(2):393-404
pubmed: 18343277
Am J Hematol. 2021 Jan;96(1):128-144
pubmed: 33064330
Lancet. 2003 May 24;361(9371):1801-9
pubmed: 12781551
Orphanet J Rare Dis. 2017 May 31;12(1):106
pubmed: 28569181